Bozek A, Grzanka A, Canonica GW. Omalizumab Plus House Dust Mite Immunotherapy for Asthma: A Randomised, 5-Arm, Non-Blinded, Non-Placebo-Controlled, Multicentre, Interventional Trial. Clin Exp Allergy 2025 Feb 23. doi: 10.1111/cea.70021.
PMID: 39988448